Exelixis, Inc. (NASDAQ:EXEL) is a San Francisco based, oncology focused biotechnology company developing small molecule therapies for the treatment of cancer. It is heavily focused on its promising lead product Cometriq (cabozantinib). The FDA approved cabozantinib on November 29, 2012 for the treatment of progressive metastatic medullary thyroid cancer [MTC] and will likely expand its approval for treatment of several other cancers.
Exelixis intends to develop broadly-active cabozantinib "into a major oncology franchise." The drug is currently the subject of dozens of clinical studies, and was recently featured in 9 different presentations at the 2013 meeting of the American Society of Clinical Oncology [ASCO]. I'm going to break down several of the meeting's highlights that suggest the drug...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|